What is the primary goal of Novo Nordisk's partnership with OpenAI, according to CEO Mike Doustdar?

According to CEO Mike Doustdar, the primary goal is not to replace scientists but to 'supercharge them'—using AI to lift productivity, work faster and more effectively, and reduce the need for rapid headcount growth, while maintaining human oversight and not cutting the current workforce.

How does Novo Nordisk plan to integrate OpenAI's technology across its operations, and what timeline has it set for full implementation?

Novo Nordisk plans to deploy OpenAI's technology across research and development, manufacturing, and commercial operations through pilot programmes, with full integration targeted by the end of 2026; the collaboration includes using AI to analyse complex datasets, identify promising drug candidates, improve manufacturing and supply chain efficiency, support regulatory filings, and train its global workforce to boost AI literacy and productivity.

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development

Apr 13, 2026

Novo Nordisk partners with OpenAI to deploy AI across drug discovery, manufacturing, and supply chains. The move aims to boost efficiency and competitiveness in the lucrative weight-loss drug market, targeting full integration by late 2026.

reuters

2026-02-25

Novo Nordisk Taps Start-Up for New Oral Weight-Loss Drugs

2026-04-13

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development

2026-04-23

Novo Nordisk's Oral GLP-1 Drug Meets Primary Goal in Late-Stage Diabetes Study

2026-05-05

Novo Nordisk's first-quarter profit beats forecasts

2026-05-26

Global Firms Bring More Work In-House at India Hubs on AI Boost